HEALTHCNBC TOP
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Shares of French biotech Abivax fell 32% following updated trial data on its lead asset for bowel disease. The stock decline occurred after the company reported fresh data on its primary drug candidate.
Related Signal
Adjacent reporting
- Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death
- Obesity Firm Kailera Therapeutics Up 63% After $625 Million IPO
- Hims & Hers plummets 15% after first-quarter loss, weak earnings guidance
- STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
- STAT+: Johnson & Johnson advances IBD therapy, despite trial miss
- STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more